Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Nov 11, 2023 12:32pm
75 Views
Post# 35730209

RE:RE:RE:Options

RE:RE:RE:OptionsInteresting  about  10,000,000  taken by retail investors.  Was that  a long time  ago??

Anyway,  looking at the dermal injector  , I  still do not see it as a money maker.  If it is good  tech  , people will copy  and change a little bit to  circumvent the patents.  This has taken so long  someone  must  be on top of this.

the other issue is that  'hardware'  usually  is  not a longterm  money  maker.  Most applications  , the  almost  give you the  hardware because the money is in the 'Down the Drain'  supplies

Kodak  cameras  and  film   computer printers and  ink   Etc.

Too much competition  in  hardware  -  look at  photo copiers  etc.

Just  saying  we should not be  broadcasting a low price for a buyout  as  once the chalk goes on the wall  , someone will go lower.  They  can always try to sell this as a shell  company  but that  means a rollback  (now nicely called a  reverse split)  and unless  they  have a super  project to roll into it.  the actual  shareholder value  is likely  even less than  1  cent

Just  saying  and hoping  not

GLTA
<< Previous
Bullboard Posts
Next >>